ZZ Biotech

Executive Summary

ZZ Biotech is a private, Houston-based biotechnology company focused on developing recombinant protein therapies for ischemic stroke and other neurological disorders. Its lead candidate, 3K3A-APC, is a variant of activated protein C designed to provide neuroprotection and reduce inflammation in stroke patients. The company is also exploring the application of its platform in dermatology. Founded in 2012, ZZ Biotech has advanced 3K3A-APC through preclinical and early clinical studies, but remains at a relatively early stage with no approved products. The company's proprietary technology targets unmet needs in stroke, where existing treatments have limited time windows and efficacy. With a novel mechanism of action and potential for expanded indications, ZZ Biotech represents a speculative opportunity in the neurology space, but lacks substantial public data on recent financing or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2a trial for 3K3A-APC in ischemic stroke40% success
• Q2 2027Preclinical data readout for dermatology application of 3K3A-APC25% success
• Q1 2027Potential partnering or licensing deal for 3K3A-APC15% success